The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The potential of differentiation therapies for AML
Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses the efficiency of differentiation therapies for the elimination of acute myeloid leukemia at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH). Dr de Botton emphasizes the need to further improve results via the use of combination therapies, and describes how enasidenib can be combined with a wide variety of targeted drugs and other agents.
